ClinicalTrials.gg
RecruitingNCT07619157Updated Jun 8, 2026

A Study of ONO-3310 in Healthy Adult Male Subjects and Chronic Kidney Disease Patients With Type 2 Diabetes Mellitus

A Phase 1 interventional study of ONO-3310 and Placebo in Type2 Diabetes Mellitus and Chronic Kidney Disease, sponsored by Ono Pharmaceutical Co., Ltd.. Recruiting at 1 site in Japan. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-08.

Sponsored by Ono Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
120
Allocation
Non-randomized
Ages
18 Years to 64 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 102 studies in Renal Insufficiency, Chronic with a site in Japan — 13 open to participants now, 21 under way, 12 of them phase 3. Renal Insufficiency, Chronic · Japan.

Planned enrollment
58th of 88
120 · median 216
Started
2026
with 5 others
Phase 1
5 of 102
1 open now
Primary completion
2027-11
later than 10 of 20 live
Registered
98th of 102
by date

Among the 102 studies in Renal Insufficiency, Chronic with a site in Japan, this one is the 58th largest by planned enrollment of the 88 interventional ones that give a count, is one of 6 that started in 2026, is one of 5 in phase 1, reaches primary completion later than 10 of the 20 other live ones, and was the 98th registered.

Renal Insufficiency, Chronic

3,097 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

13 of the 102 studies in Renal Insufficiency, Chronic with a site in Japan are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 435 Renal Insufficiency, Chronic studies recruiting now, 246 (57%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 64 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 102 studies in Renal Insufficiency, Chronic with a site in Japan, or all of them as a file.
02

Study summary

To investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of ONO-3310 in healthy Japanese adult male subjects and chronic kidney disease patients with type 2 diabetes mellitus

Read the detailed description

To investigate the safety, tolerability, and pharmacokinetics of single and multiple oral doses of ONO-3310 in healthy Japanese adult male subjects. In addition, in chronic kidney disease patients with type 2 diabetes mellitus, to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of ONO-3310.

03

Conditions studied

  • Type2 Diabetes Mellitus
  • Chronic Kidney Disease
04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Healthy adult part

  1. Japanese healthy adult male subjects
  2. Age at the time of : 18 to 45
  3. (at screening): 18.5 kg/m2 to less than 25.0 kg/m\^2

Chronic kidney disease patient part

  1. Chronic kidney disease patients with type 2 diabetes mellitus
  2. Age at the time of informed consent: 18 to less than 65
  3. UACR measured by 24-hour urine collection: 300 mg/g to less than 3500 mg/g

Exclusion criteria

Exclusion Criteria:

Healthy adult part

  1. Subjects who currently receive treatment for or have a history of any of the following diseases: respiratory system, cardiovascular system, psychiatric system, nervous system, gastrointestinal system, immune system, liver, kidney, hematopoietic function, or endocrine function.
  2. Presence or history of severe allergy to drugs or food
  3. Presence or history of drug or alcohol dependence

Chronic kidney disease patient part

  1. Current symptoms of severe, progressive, or uncontrolled hepatic, hematologic, gastrointestinal, pulmonary, psychiatric, cardiac, endocrine, neurologic, or cerebral disease
  2. Patients with type 1 diabetes mellitus
  3. Patients with a history of dialysis treatment
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Single-dose ONO-3310

    Drug: ONO-3310

  • Placebo comparator
    Single-dose placebo

    Drug: Placebo

  • Experimental
    Multiple-dose ONO-3310

    Drug: ONO-3310

  • Placebo comparator
    Multiple-dose placebo

    Drug: Placebo

  • Experimental
    Single- and multiple-dose ONO-3310

    Drug: ONO-3310

Interventions

  • DrugONO-3310

    Single oral dose of ONO-3310 to HV

  • DrugPlacebo

    Single oral dose of Placebo to HV

  • DrugONO-3310

    Multiple oral dose of ONO-3310 to HV

  • DrugPlacebo

    Multiple oral dose of Placebo to HV

  • DrugONO-3310

    Single or multiple oral dose of ONO-3310 to CKD patients

06

What researchers measure

Primary outcomes

  1. Adverse event

    Number of participants with adverse events

    Time frame: Through study completion, typically 10days (HV single), 23 days (HV multiple), and 74 days (CKD)

  2. Maximum plasma observed concentration (Cmax)

    Time frame: Up to 10 days (HV single), 23 days (HV multiple), and 74 days (CKD)

  3. Time to reach maximum observed concentration (Tmax)

    Time frame: Up to 10 days (HV single), 23 days (HV multiple), and 74 days (CKD)

  4. Area under the plasma concentration versus time curve from time zero to 24 hours (AUC24h)

    Time frame: Up to 10 days (HV single), 23 days (HV multiple), and 74 days (CKD)

  5. Area under the plasma concentration versus time curve from time zero to infinity (AUCinf)

    Time frame: Up to 10 days (HV single), 23 days (HV multiple), and 74 days (CKD)

  6. Area under the plasma concentration versus time curve from time zero to time of last measurable concentration (AUClast)

    Time frame: Up to 10 days (HV single), 23 days (HV multiple), and 74 days (CKD)

  7. Elimination half-life (T1/2)

    Time frame: Up to 10 days (HV single), 23 days (HV multiple), and 74 days (CKD)

  8. Apparent total clearance (CL/F)

    Time frame: Up to 10 days (HV single), 23 days (HV multiple), and 74 days (CKD)

  9. Urinary excretion rate of unchanged drug

    Time frame: Up to 6 days (HV single)

  10. Pharmacodynamics (evaluation of Urinary albumin-to-creatinine ratio)

    Time frame: Up to 74 days (CKD)

07

Study locations

1 of 1 sites recruiting
  • Souseikai Hakata Clinic
    Fukuoka, Fukuoka, Japan
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Nov 2027, 17 months after the start.

Of 77 industry-sponsored phase 1 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's planned 17 months is above that.

Counting every sponsor, half of 109 studies reached it within 11 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2026
First posted
Jun 1, 2026
StartActual
Jun 2, 2026
Primary completionEst.
Nov 30, 2027
CompletionEst.
Nov 30, 2027
Last update
Jun 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07619157
Responsible party
Sponsor
First posted
Jun 1, 2026
Start date
Jun 2, 2026
Primary completion
Nov 30, 2027 (estimated)
Completion
Nov 30, 2027 (estimated)
Last update
Jun 8, 2026

Study contacts

Ono Pharmaceutical Co., Ltd.
Contact
clinical_trial@ono-pharma.com
+18665877745
International Clinical Trial Support Desk
Contact
clinical_trial@ono-pharma.com
+17162141777
Project Leader
study director · Ono Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion